Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome.

Hdl Handle:
http://hdl.handle.net/10675.2/174
Title:
Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome.
Authors:
Mathur, Ruchi; Levin, Olga; Azziz, Ricardo ( 0000-0002-3917-0483 )
Abstract:
Polycystic ovary syndrome (PCOS) is one of the most common endocrine/metabolic disorders found in women, affecting approximately 105 million women worldwide. It is characterized by ovulatory dysfunction, often presenting as oligomenorrhea or amenorrhea and either clinical or biochemical hyperandrogenism. Combined oral contraceptive (COC) therapy has long been a cornerstone of care for women with PCOS. COC therapy often provides clinical improvement in the areas of excessive hair growth, unpredictable menses, acne, and weight gain. One of the main issues in COC therapy is choosing the most appropriate progestin component to provide the greatest anti androgenic effects. Drospirenone, a relatively new progestin, has shown benefit in the PCOS population when used in conjunction with ethinyl estradiol. We now review the role of COCs in PCOS, focusing specifically on drospirenone. Controversy over metabolic effects of COCs in PCOS is also discussed.
Publisher:
Dove Medical Press
Issue Date:
27-Aug-2008
URI:
http://hdl.handle.net/10675.2/174
PubMed ID:
18728832
PubMed Central ID:
PMC2504056
ISSN:
1176-6336
Appears in Collections:
President's Research and Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMathur, Ruchien_US
dc.contributor.authorLevin, Olgaen_US
dc.contributor.authorAzziz, Ricardoen_US
dc.date.accessioned2010-11-17T20:16:05Z-
dc.date.available2010-11-17T20:16:05Z-
dc.date.issued2008-08-27en_US
dc.identifier.issn1176-6336en_US
dc.identifier.pmid18728832en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/174-
dc.description.abstractPolycystic ovary syndrome (PCOS) is one of the most common endocrine/metabolic disorders found in women, affecting approximately 105 million women worldwide. It is characterized by ovulatory dysfunction, often presenting as oligomenorrhea or amenorrhea and either clinical or biochemical hyperandrogenism. Combined oral contraceptive (COC) therapy has long been a cornerstone of care for women with PCOS. COC therapy often provides clinical improvement in the areas of excessive hair growth, unpredictable menses, acne, and weight gain. One of the main issues in COC therapy is choosing the most appropriate progestin component to provide the greatest anti androgenic effects. Drospirenone, a relatively new progestin, has shown benefit in the PCOS population when used in conjunction with ethinyl estradiol. We now review the role of COCs in PCOS, focusing specifically on drospirenone. Controversy over metabolic effects of COCs in PCOS is also discussed.en_US
dc.description.urihttp://www.dovepress.com/articles.php?article_id=1317en_US
dc.publisherDove Medical Pressen_US
dc.rightsThe PMC Open Access Subset is a relatively small part of the total collection of articles in PMC. Articles in the PMC Open Access Subset are still protected by copyright, but are made available under a Creative Commons or similar license that generally allows more liberal redistribution and reuse than a traditional copyrighted work. Please refer to the license statement in each article for specific terms of use. The license terms are not identical for all articles in this subset.en_US
dc.titleUse of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome.en_US
dc.identifier.pmcidPMC2504056en_US
dc.contributor.corporatenameCedars-Sinai Medical Center, Los Angeles, CAen_US
All Items in Scholarly Commons are protected by copyright, with all rights reserved, unless otherwise indicated.